B. Supportive. The H.E.L.P. System. A Physician Guide to LDL Apheresis Therapy
|
|
- Neil Dean
- 5 years ago
- Views:
Transcription
1 The H.E.L.P. System (Heparin-induced Extracorporeal Lipoprotein Precipitation) A Physician Guide to LDL Apheresis Therapy When drugs and diet alone can t reduce LDL cholesterol, H.E.L.P. therapy can. B. Supportive.
2 A Procedural Overview of H.E.L.P. Therapy A H.E.L.P. procedure is a continuous, closed-loop process involving removal of whole blood and return of cellular blood components and filtered, cleansed plasma to the patient s circulation. Over a 1.5 to 2-hour treatment session, an average of between 2.5 and 3.0 liters of plasma is treated. The H.E.L.P. System is extremely efficient in the elimination of LDL, Lp(a) and fibrinogen from processed plasma. Performed by a trained nurse, the H.E.L.P. process involves five basic stages: Blood withdrawn from the patient is continuously separated into plasma and cellular components by passage through a capillary plasma filter. Cellular components are returned directly to the patient. BUFFER/HEPARIN 1 2 A mixture of sodium acetate buffer (ph 4.85) and heparin (100 IU/ml) are added to the plasma in equivalent parts by volume. When ph is adjusted to 5.12, lipoprotein complexes form a precipitate. CAPILLARY PLASMA FILTER 1 CELLS PLASMA PRECIPITATE FILTER 3 The precipitated lipoprotein complexes are captured in the precipitate filter, which is later discarded. ULTRA-FILTER HEPARIN ADSORBER Physiologic ph of LDL- and heparin-free plasma is corrected with bicarbonate dialysis, followed by ultrafiltration to correct volume. 5 4 Residual heparin is removed from the LDL-free plasma by a heparin adsorber. As for all apheresis procedures, the three available options for venous access include (1) left and right side arm veins, (2) arteriovenous fistula and (3) central venous access. At any given time during treatment, the total volume of cellular blood components and plasma which are extracorporeal (withdrawn from the body) never exceeds 150 ml and 400 ml, respectively about one unit of blood. All tubing and filters are sterile, disposable and single use only. The frequency of therapy depends on the individual patient, but heterozygotes are most commonly scheduled for treatment every two weeks. Homozygotes typically require weekly therapy to attain sufficient average LDL lowering.
3 REFERENCES 1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): Neaton JD and Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med 1992; 152: Goldstein JL, Hobbs HH and Brown MS. Chapter 62: Familial Hypercholesterolemia. In: C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle (eds). The Metabolic and Molecular Bases of Inherited Disease, Ed. 7, pp McGraw-Hill, Schuff-Werner P, Gohlke H, Bartmann U, et al. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease. Eur J Clin Invest 1994; 24: Lane DM, McConathy WJ, Laughlin LO, et al. Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy. Atherosclerosis 1995; 114: Jaeger BR. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis. Therapeutic Apheresis 2001; 5(3): Lane DM, Alaupovic P, Knight-Gibson C, et al. Changes in plasma lipid and apoliprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments. Am J Cardiol 1995; 75: Seidel D, Armstrong VW and Schuff-Werner P. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Investig 1991; 21: Thompson SG, Kienast J, Pyke STM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995; 332: Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83: Kostner G, Avogara P, Cazzolato G, et al. Lipoprotein (a) and the risk of myocardial infarction Atherosclerosis 1981; 38: Rhoads G, Dahlen G, Berg K, et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256: Craig W, Neveuz L, Palomaki G, et al. Lipoprotein (a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies. Clin Chem 1998; 44: Spinler S, Cziraky M. Lipoprotein (a): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacotherapy 1994; 28: Illingworth D, Stein E, Mitchel Y, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154: Moriarty PM, Gibson CA, Kensey KR and Hogenauer W. Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. Am J Cardiol 2004; 93: Seidel D. HELP apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artificial Organs 1996; 20(4): Harkness J. Measurement of plasma viscosity. In Clinical Aspects of Blood Viscosity and Cell Deformability. Lowe GD, Barbanei JC and Forbes CD, eds. Berlin: Springer-Verlag; 1981: Koenig W, Homback V, Ernst E, et al. Plasma viscosity as a cardiovascular risk factor. Circulation 1992; 86: Mellwig K-P, Baller D, Gleichmann U, et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998; 139: Kleophas W, Leschke M, Tschope D, et al. Acute effects of extracorporeal LDL cholesterol and fibrinogen elimination on blood rheology and microcirculation. Dtsch Med Wochenschr 1990; 115: Nissen SE, Tuzcu ME, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004; 291(9): Thiery J and Seidel D. Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Curr Opin Lipidol 1998; 9: Bertrams A and Strout N. Treatment methods for LDL apheresis. J Clin Apheresis 1994; 9: Thiery J, Meiser B, Wenke K, et al. Heparin-induced extracorporeal low-densitylipoprotein plasmapheresis (HELP) and its use in heart transplant patients with severe hypercholesterolemia. Transplantation Proceedings 1995; 27(3): Park J-W, Merz M and Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997; 16: Bosch T, Thiery J, Samtleben W, et al. Combined simultaneous LDL-apheresis and hemo-dialysis in hypercholesterolemic ESRD patients: a new mode of therapy. J Amer Soc Nephrol 1991; 2: Moriarty PM, Gibson CA, Shih J, et al. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 2001; 158: For more information, contact us at , or to rtd@bbraun.com. Rx only. H.E.L.P. is a trademark of B. Braun Medical Inc B. Braun Medical Inc., Bethlehem, PA. All rights reserved. HELP.001L rev.12/05 JH 2M
4 Safety Profile of H.E.L.P. Therapy In clinical use in Europe since 1986, 24 the safety and tolerability of H.E.L.P. therapy has been demonstrated in both clinical trials and post-approval surveillance studies involving severely hypercholesterolemic patients. Worldwide experience with H.E.L.P. therapy now exceeds 200,000 individual treatments. The H.E.L.P. procedure has also been used successfully in the treatment of post-heart transplant patients 25,26 and patients on concurrent renal dialysis. 27 A German study of 51 patients who received 4,330 H.E.L.P. treatments over a two-year period documented no serious adverse events attributable to the procedure. 4 Adverse reactions associated with H.E.L.P. therapy are those typically expected with any procedure involving circulation of blood outside the body. In the U.S. H.E.L.P. trial involving 40 patients and 2,826 treatments, venous access difficulties (2.3%) and transient hypotension (1.0%) were the most common adverse events. Venous access problems often include clotting in the needle, clotted fistula or collapsed, inadequate or sclerosed veins; all can be resolved using standard methods. Transient hypotension is usually managed by administering intravenous fluids, allowing the treatment session to be completed. Below are all other minor adverse events which occurred in at least 0.1% of procedures: Adverse Event Number (%) Chills/Shivering 9 (0.3%) Fatigue 8 (0.3%) Prolonged PTT or ACT 7 (0.2%) Nausea/Vomiting 7 (0.2%) Chest Heavy/Pain 4 (0.1%) Dizziness/Syncope 4 (0.1%) Headache 4 (0.1%) Elevated Temperature 3 (0.1%) Others (single events)* 14 (0.5%) Total treatments 2,286 *Flushing, gastrointestinal bleed, hyperventilation, wheezing, elevation of liver enzymes, apical density on CXR, ankle swelling, prostatitis, hematuria, hypoglycemia, sympathetic reflex dystrophy, angina/2nd PTCA, endarterectomy An indication of the inherent safety of the H.E.L.P. procedure is the rare need to discontinue it: in a study involving more than 4,330 treatments, only three had to be interrupted because of technical or medical problems, none of which was serious in nature. 4
5 Chronic LDL apheresis therapy In a subpopulation of patients diagnosed with familial hypercholesterolemia (FH), their seriously elevated plasma LDL cholesterol (LDL) levels fail to adequately respond to a prescribed diet and maximally tolerated combinations of lipid-lowering drugs. Chronic LDL apheresis therapy offers motivated patients a highly effective means to reduce and maintain the LDL level in a safer range, thereby minimizing its atherogenic effects and associated risks of coronary heart disease, peripheral vascular disease and premature death. The U.S. Food and Drug Administration approved the Heparin-induced Lipoprotein Precipitation (H.E.L.P. ) System for clinical use in September To date, more than 200,000 H.E.L.P. treatments have been performed worldwide to help improve the cardiovascular health of FH patients, with an excellent safety profile. Once you have had an opportunity to review the information in this Physician Guide, we hope you will decide that H.E.L.P. therapy should be part of your armamentarium for the management of carefully selected patients with severe drug-refractory hypercholesterolemia. Drug-Refractory Familial Hypercholesterolemia: The Treatment Imperative A direct causal relationship between plasma cholesterol levels and coronary heart disease (CHD) risk has been firmly established through extensive population-based and interventional studies. The current ATP III guidelines recommend an LDL goal of <100 mg/dl for patients with CHD and CHD risk equivalents. 1 A landmark 1992 population study of 361,662 middle-aged American men confirms a strong curvilinear relationship between LDL level and CHD-related mortality risk. 2 For severely hypercholesterolemic patients with relatively high baseline LDL levels, each 20 mg/dl decline achieves a much larger drop in CHD-related mortality risk than at lower baseline LDL levels (orange arrows): LDL-Cholesterol (mg/dl) Adapted from Neaton JD, Wentworth D. Arch Int Med 1992; 152:56-64 As confirmed in other studies, men with an LDL level of about 240 mg/dl can expect to have a 12-year CHD-related mortality experience at least three-fold higher than those with an LDL level of about 130 mg/dl. In untreated persons with heterozygous familial hypercholesterolemia (FH), total cholesterol levels are typically elevated more than two-fold over normal, typically ranging from 350 to 550 mg/dl. 3 For these FH patients, who have sharply elevated blood cholesterol levels from birth and commonly have a CHD history by the time they are diagnosed the mortality risk at elevated LDL levels is higher than in the general population. Intensive lipid-lowering drug therapy is usually successful in reducing LDL, both for primary and secondary prevention of CHD. In a subset of heterozygotes (as well as rare homozygotes with two defective alleles for the LDL receptor), dietary and maximally tolerated combinations of two or more lipid-lowering drugs fail to lower LDL to an acceptable range. Assuming good patient compliance, this generally occurs either because (1) the patient is resistant or refractory to drug therapy or (2) the patient cannot tolerate optimized drug combinations. For these patients, chronic LDL apheresis offers a safe and effective means to achieve and maintain a substantially reduced mean LDL level. When LDL apheresis is performed with B. Braun s Heparininduced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) System, circulating levels of certain other atherogenic and prothrombotic plasma elements are substantially reduced as well, providing additional CHD risk reduction benefits.
6 Fibrinogen levels and CHD event risk: evidence from the literature. While fibrinogen levels start to rebound immediately after each H.E.L.P. treatment session, on a time-averaged basis fibrinogen is reduced by roughly 40%. 8 Elevated fibrinogen levels have increasingly been cited as an inflammatory marker and a risk factor for CHD; it promotes adhesion of platelets and erythrocytes to the endothelium, increases plasma viscosity and participates in thrombus formation. A landmark prospective study following several thousand patients with angina pectoris over a two-year period revealed that higher baseline concentrations of fibrinogen were associated with an increased incidence of myocardial infarction or sudden death. 9 Below are coronary events data for three fibrinogen level tertiles: Risk of coronary events stratified on baseline fibrinogen level in anginal patients followed for a two-year period Plasma fibrinogen Coronary events/ Risk of coronary level patients events (%) <270 mg/dl 12/ % mg/dl 35/ % <330 mg/dl 42/ % Remarkably, in the patients with fibrinogen levels under 270 mg/dl, coronary event risk remained low even in the presence of elevated serum cholesterol levels: the risk of coronary events was 1.3% in patients with total cholesterol <224 mg/dl and was 1.2% in those with >263 mg/dl. A still larger UK study of 4,860 middle-aged men confirmed the association between fibrinogen level and coronary events: the age-adjusted relative risk of ischemic cardiac events for men in the top 20% of the fibrinogen level distribution compared to the bottom 20% was Lp(a): another atherogenic factor reduced by H.E.L.P. therapy. A number of investigations report a strong association between elevated levels of lipoprotein (a), or Lp(a), and increased incidence of coronary artery disease. 11,12,13 Because Lp(a) levels are under genetic control, efforts to modify elevated levels through diet and exercise have not proven successful. Niacin alone or in combination with a bile acid sequestrant or neomycin can reduce Lp(a) levels, 14 but HMG-CoA reductase inhibitor therapy does not appear to offer benefit. 15 H.E.L.P. therapy acutely reduces Lp(a) levels by the same low ph heparin precipitation mechanism that selectively removes LDL and triglycerides. Reduced blood viscosity: lower CHD event risk. Immediately following H.E.L.P. treatment, patients experience a 15% mean reduction in blood viscosity. 16,17 This blood viscosity effect is substantially attributable to reductions in levels of fibrinogen, plasma LDL and other lipoproteins. Due to its large size (341 kd) and length, fibrinogen in particular contributes 20% to 25% to plasma viscosity. 18,19 Conversely, elevated blood viscosity has been shown to be positively associated with initial and repeat CHD events. 10 While additional trials are needed to evaluate the relation between reduced blood viscosity by LDL apheresis and its effects on vascular disease, a single H.E.L.P. treatment has been shown to increase endothelial function and enhance coronary vasodilatory capacity and increase exercise capacity. 21 Stabilization or regression of coronary stenoses. A number of studies have demonstrated that LDL-lowering drug therapy can reduce or halt the progression of coronary atheromas. 22 Similarly, in a multicenter evaluation of 187 coronary segments in 33 patients undergoing H.E.L.P. therapy, 103 segments with >30% stenosis had a mean 4.3% reduction (p<0.001) in stenosis after two years of regular treatment. 4 Reduced incidence and severity of angina pectoris. In a German study evaluating the H.E.L.P. System in 39 patients with existing coronary heart disease, the share of patients who were free of anginal symptoms increased from 18% prior to treatment, to 38% over two years of regular H.E.L.P. therapy. 4 In a separate post-marketing surveillance study involving 413 patients over a mean 5-year period, chronic H.E.L.P. therapy reduced complaints of angina pectoris, and appeared to be protective in non-anginal patients at first examination: Among patients (n=178) with anginal complaints at first examination (pre-h.e.l.p.) Status No. (%) with anginal complaints at final exam No change 41 (23.0%) Improvement 85 (47.8%) Disappearance 52 (29.2%) Among patients (n=235) without anginal complaints at first examination (pre-h.e.l.p.) Status No. (%) with anginal complaints at final exam No change 220 (93.6%) Intercurrent angina 11 (4.7%) Anginal complaints 4 (1.7%) Evidence of reduced risk for acute cardiovascular events. A pair of long-term studies in patients with pre-existing CHD and hypercholesterolemia offer strong suggestive evidence that H.E.L.P. therapy mediates a sharp reduction in the risk of myocardial infarction and other major cardiovascular events. 23
7 H.E.L.P. LDL Apheresis Therapy: Acute and Reduction of Risk Factor Proteins For properly selected FH patients who do not adequately respond to medications and diet, chronic H.E.L.P. therapy achieves a substantial reduction in time-averaged LDL level. H.E.L.P. therapy also selectively reduces the circulating levels of a number of other atherogenic and prothrombotic blood elements implicated as risk factors for CHD-related events: 4,5,6 Acute reductions in selected blood markers following a single H.E.L.P. treatment session LDL-C Lp(a) Triglycerides Fibrinogen Pre-treatment Post-treatment C-reactive protein* 60% 65% 55% 55% 50% While each H.E.L.P. procedure marginally reduces plasma highdensity lipoprotein cholesterol (HDL) by 10-15%, the level of this good cholesterol generally returns to baseline within two days. 7 Over several months of H.E.L.P. therapy, the pretreatment HDL level rises to exceed the baseline level by an average of 15%. 5,8 The mechanism responsible for this beneficial HDL effect is not known. The highly selective H.E.L.P. procedure also conserves antibodies, albumin, coagulation factors and other important circulating blood elements. 5 Time-Averaged LDL Lowering. Immediately following a H.E.L.P. treatment session, the sharply reduced levels of LDL, Lp(a), fibrinogen and other proatherosclotic and pro-thrombotic elements promptly begin to rise. This rebound effect generally necessitates biweekly H.E.L.P. therapy for most heterozygotes and weekly therapy for homozygotes. Confirming earlier European experience, a clinical trial documented a time-averaged LDL reduction of nearly 140 mg/dl with biweekly H.E.L.P. treatments. 5 Notably, pre-treatment LDL levels decline more than 50 mg/dl after regular long-term H.E.L.P. therapy, to reach a new lower pre-treatment baseline. Similarly, the immediate posttreatment LDL trough level continues to decline with regular therapy to a new lower steady state. This pattern applies also for plasma triglycerides, Lp(a) and fibrinogen. 8 PRIOR TO H.E.L.P. THERAPY ON H.E.L.P. THERAPY Baseline LDL LDL Cholesterol Time Pre-treatment LDL level Time-averaged LDL level Post-treatment LDL trough level * Over a six-month study period with biweekly H.E.L.P. therapy, CRP levels exhibited a mean 49% reduction from baseline in four drug- and diet-resistant FH patients with advanced coronary artery disease. 28
8 Insurance Coverage and Billing for H.E.L.P. Therapy Coverage H.E.L.P. therapy is consistently covered by Medicare and private health insurers when prescribed for the chronic management of high-risk hypercholesterolemic patients for whom dietary and maximum tolerated drug and dietary therapy fails to achieve adequate LDL cholesterol reduction. Private insurers and state Medicaid programs generally require preauthorization before submitting claims for this service. Suggested guidelines for securing preauthorization are available at your request. Insurance coverage policies have generally been modeled on the September 1997 FDA marketing approval for the H.E.L.P. System. Patients who have failed a minimum six-month trial of an American Heart Association (AHA) Step II diet (or equivalent) and maximum tolerated combination drug therapy are eligible for H.E.L.P. therapy when they fall into one of the following three groups: Functional hypercholesterolemic heterozygotes with LDL > 200 mg/dl and documented coronary heart disease (CHD)* Functional hypercholesterolemic heterozygotes with LDL > 300 mg/dl Functional hypercholesterolemic homozygotes with LDL > 500 mg/dl As a physician, you have the prerogative to recommend and provide H.E.L.P. therapy for patients whose baseline LDL levels do not happen to fall within the confines of this indication, but you should be prepared to justify its medical necessity to the satisfaction of the patient s insurer. Many insurers will preauthorize a specified number of H.E.L.P. treatments, or for a specified duration, at which time updated clinical laboratory results will be required to secure a new preauthorization. This is a routine policy for coverage of many chronic therapeutic modalities. Supporting Your H.E.L.P. LDL Apheresis Program: The B. Braun Commitment H.E.L.P. therapy programs can be situated in either hospital or non-hospital settings, usually under the direction of a specialist in cardiology, internal medicine or endocrinology. B. Braun Medical provides all technical support services and operator training on the H.E.L.P. System to get your team ready to deliver patient therapy. Lipid Clinic Cardiology Clinic HOSPITAL On an ongoing basis, B. Braun commits to support your LDL apheresis program with: New staff training New clinical and scientific literature Reimbursement consultation Patient literature H.E.L.P. program marketing assistance Blood Bank PHYSICIAN-DIRECTED CLINIC Lipid Clinic Cardiology Clinic Apheresis Clinic Blood Center We understand that we succeed as a supplier of this enabling technology by helping you succeed as a H.E.L.P. therapy provider. Finally, while this procedure offers the promise of extended lifespan and enhanced quality of life, it is important to emphasize to patients that it also requires a long-term commitment on their part. Good candidates for H.E.L.P. therapy are those who are also sufficiently motivated to visit your clinic for their biweekly or weekly treatment sessions on an indefinite basis. Billing For hospital-based H.E.L.P. therapy programs, the hospital bills the technical procedure and the physician s practice group separately bills his or her professional services. For non-hospital-based H.E.L.P. programs, a single claim is submitted. Some insurers define separate payment amounts for technical and professional components of this service, while others prefer to set a single global payment rate. * CHD is defined as having one or more of the following: a prior documented myocardial infarction (MI); a prior coronary bypass graft surgery (CABG); a prior percutaneous transluminal coronary angioplasty (PTCA) with or without atherectomy or coronary stent placement; and significant angina pectoris with a positive thallium or other heart scanning stress test.
LIPOPROTIEN APHERESIS. Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center
LIPOPROTIEN APHERESIS Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center OUTLINE Familial Hypercholesterolemia (FH) Diagnosis Treatment options Lipoprotein apheresis Procedures Expected
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationTreatment of severe Familial Hypercholesterolemia LDL Apheresis
Treatment of severe Familial Hypercholesterolemia LDL Apheresis Identifying and Treating Severe Familial Hypercholesterolemia October 14-15, 2017 Dubai, UAE Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior
More informationCorporate Medical Policy Lipid Apheresis
Corporate Medical Policy Lipid Apheresis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: lipid_apheresis 11/2013 4/2017 4/2018 5/2017 Description of Procedure or Service Therapeutic
More informationClinical Policy Title: Lipoprotein apheresis
Clinical Policy Title: Lipoprotein apheresis Clinical Policy Number: 04.03.07 Effective Date: October 1, 2016 Initial Review Date: June 15, 2016 Most Recent Review Date: June 22, 2017 Next Review Date:
More informationSeung-Hwan Lee, M.D., Ph.D.
2015.10.16. ICDM, DMJ session Statin discontinuation after achieving a target low-density lipoprotein cholesterol level in type 2 diabetic patients without cardiovascular disease: a randomized controlled
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationOutpatient Cardiac Rehabilitation
Last Review Date: May 12, 2017 Number: MG.MM.ME.26bC3v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More informationPopulations Interventions Comparators Outcomes Individuals: With diagnosed heart disease. rehabilitation
Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 01/01/17 Next Review Date: 05/18 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationLIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS Patrick M. Moriarty, M.D., FACP, Director, Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical
More informationCurrent Treatment Of Ischemic Heart Disease In the United States: An Overview. By Dr Gary Mo
Current Treatment Of Ischemic Heart Disease In the United States: An Overview By Dr Gary Mo 1 Ischemic Heart Disease in the US 1. Cardiovascular disease remains the most common cause of death and is responsible
More informationLp(a) Ready for prime time? E Stroes AMC
Lp(a) Ready for prime time? E Stroes AMC Case Male, 45 years old Hypertension: DM: Smoking: Dyslipidemia: Fam history: brother MI (55yr) Lipoprotein(a): 1240 mg/l!!! Lipoprotein(a) = LDL + apo(a) tail
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationLipid Apheresis. Description
Subject: Lipid Apheresis Page: 1 of 10 Last Review Status/Date: December 2014 Lipid Apheresis Description Therapeutic apheresis describes a variety of technologies used to remove select components from
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationNephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler
Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9- Inhibitors, Lipoprotein Apheresis or
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCardiovascular Concerns in Intermediate Care
Cardiovascular Concerns in Intermediate Care GINA ST. JEAN RN, MSN, CCRN-CSC CLINICAL NURSE EDUCATOR HEART AND & CRITICAL AND INTERMEDIATE CARE Objectives: Identify how to do a thorough assessment of the
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationJuxtapid and Kynamro
DRUG POLICY Juxtapid and Kynamro BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationSupplementary Online Content
Supplementary Online Content Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationMeasurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date
MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More information4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose
DYSLIPIDEMIA CASES Mary Malloy, MD I have nothing to disclose 1 Case 1 A 24 year old healthy, slender woman is referred because she has a family history of premature CAD (mother, age 59, had onset of angina
More informationQuestions and Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Heart Disease
Questions and Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Heart Disease Results from the Trial to Assess Chelation Therapy will be published in the Journal of the American Medical Associatio
More informationLipid Apheresis. Policy Number: Last Review: 4/2018 Origination: 4/2005 Next Review: 4/2019
Lipid Apheresis Policy Number: 8.02.04 Last Review: 4/2018 Origination: 4/2005 Next Review: 4/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for lowdensity lipid
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More information11/19/2013. Cardiac Rehabilitation Coverage and Documentation Requirements. Phases of Cardiac Rehabilitation. Phase II
Cardiac Rehabilitation Coverage and Documentation Requirements Phases of Cardiac Rehabilitation Phase I: Acute in-hospital phase of CR Phase II: is the initial outpatient phase of the program Phase III:
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationLink between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention Rabah M, Mason D, Muller D W, Hundley R, Kugelmass
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More information2019 ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule
ABBOTT REIMBURSEMENT GUIDE CMS Physician Fee Schedule This document and the information contained herein is for general information purposes only and is not intended and does not constitute legal, reimbursement,
More informationLDL Apheresis: Familial Hypercholesterolemia
LDL Apheresis: Familial Hypercholesterolemia Joyce L Ross, MSN, CRNP, CCS, FNLA, FPCNA Certified Clinical Specialist, Diplomat ACCL Past President PCNA Immediate Past President National Lipid Association
More informationEffects of Statins on Endothelial Function in Patients with Coronary Artery Disease
Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationCardiovascular Diseases and Diabetes
Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular
More informationNEW INTERVENTIONAL TECHNOLOGIES
by Lawrence M Prescott, PhD NEW INTERVENTIONAL TECHNOLOGIES EXPAND TREATMENT OPTIONS FOR CARDIOVASCULAR DISEASE Novel interventional techniques are proving to be of particular value in the treatment of
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationFocus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013 Conflicts CMO for The FH Foundation Pre-talk quiz What is cascade screening? 1. screening all family members 2.
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More informationCardiac Rehabilitation after Primary Coronary Intervention CONTRA
DEBATE SESSION Is there a role for cardiac rehabilitation in the modern era of Percutaneous coronary intervention and coronary artery bypass grafting? Cardiac Rehabilitation after Primary Coronary Intervention
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationCardiac Rehabilitation
Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health Plan Arizona, Inc.) Staywell of Florida
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Caduet) Reference Number: CP.CPA.237 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More information1 Description. 2 Indications. 3 Warnings ASPIRATION CATHETER
Page 1 of 5 ASPIRATION CATHETER Carefully read all instructions prior to use, observe all warnings and precautions noted throughout these instructions. Failure to do so may result in complications. STERILE.
More informationAttending Physician Statement- Coronary Artery Disease / Coronary Artery Surgery
Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Coronary artery disease
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationLecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors
Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationBy Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular
Lipid-Lowering Therapy For Acute Coronary Syndromes There is a large amount of evidence that supports the early use of statins in the treatment of acute coronary syndromes. The anti-inflammatory, anti-thrombotic
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationChronic Benefit Application Form Cardiovascular Disease and Diabetes
Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More information